Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Drug Discovery
- Drug delivery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 368492
Licensor of Canada grants to Licensee of Canada an exclusive license in the Territory under the Licensee Sponsored Intellectual Property to research, develop, make and have made, use and have used, sell and have sold, import and to distribute, market, lease, license or sublicense and to have distributed, marketed, leased, licensed or sublicensed the Royalty-Bearing Products and any precursors to a potential Royalty-Bearing Product.
This agreement includes non-exclusive grants back to Licensor by Licensee.
Prior IP includes these inventions
Lipid Carrier Compositions with protected surface reactive functions;
Low cholesterol containing liposomes for use in drug delivery;
Cryostable liposome compositions;
Method for encapsulation of anticancer drugs in cholesterol free liposomes;
A hybrid CTL-epitope delivery system comprising a liposomal formulation of the antenopedia homeodoman; and,
DNA-triggered drug release from liposomes for tumor specific drug delivery.
Lipid Carrier Compositions with protected surface reactive functions; and,
Low Cholesterol containing liposomes for application controlled drug delivery.
— research relating to lipid-based carriers with low levels of cholesterol (less than 30% by weight),
— research relating to therapeutically active lipids, including, without limitation, ceramides, phosphatidylinosital (PI) and phosphatidylserine (PS),
— research relating to lipid-based carriers with reactive surfaces, including, without limitation, carriers with negatively charged surfaces, positively charged surfaces and/or surfaces comprised of modified lipids,
— research relating to the identification and development of anticancer agent combination and formulations comprising such combinations; and
— such other research as may be agreed by the parties under an R&D Work Schedule; but shall exclude any clinical trials of compounds or formulations developed pursuant to this Agreement.
IPSCIO Record ID: 28952
Camptothecin is a cytotoxic quinoline alkaloid discovered in the screening of natural products for anticancer drugs. It was isolated from the bark and stem of Camptotheca acuminata (Camptotheca, Happy tree), a tree native to China used as a cancer treatment in Traditional Chinese Medicine, showing anticancer activity in preliminary clinical trials but also low solubility and (high) adverse drug reaction. CPT analogues have been approved and are used in cancer chemotherapy.
The license is for the rights to deliver paclitaxel or analogues thereof, alone or in combination with another drug, in liposomes, lipid complexes or other liposome particles, to the respiratory tract via aerosol droplets.
The methods, composition, and information claimed in U.S. Patent No. 5,049,388, entitled Small Particle Aerosol Liposome and Liposome-Drug Combinations for Medical Use and U.S. Patent Application Serial No. 08/933,254, entitled Small Particle Liposome Aerosols for Delivery of Anti-Cancer Drugs.
IPSCIO Record ID: 362429
Licensor grants to Licensee a revocable, limited, non-exclusive, non-transferable license in the United States and European Union member countries to use Licensorâ€™s Trademark â€œSMARTICLESÂ® liposomal delivery technologyâ€ and in all other countries in the Territory â€œSMARTICLESâ„¢ liposomal delivery technologyâ€ solely to research, develop, promote and sell Licensed Products. Notwithstanding the foregoing, any use or display of the Trademark by Licensee shall be in a manner that the Parties agree is commercially reasonable, which approval by Licensor shall not be unreasonably withheld. Licensor may, at its discretion, independently monitor Licenseeâ€™s use of the Trademark, and if Licensor perceives a use or display of its Trademark that is not in accordance with preciously approved submissions or is otherwise damaging to Licensor, Licensor may notify Licensee of such and Licensee shall correct such non-conformance or shall cease and desist such use or display within thirty (30) days of receipt of such notice.
Licensed Patent means
7,371,404 – Amphoteric liposomes are proposed, which comprise positive and negative membrane-based or membrane-forming charge carriers as well as the use of these liposomes.
7,780,983 – Amphoteric liposomes
7,858,117 – Amphoteric liposomes and their use
Licensee Compound means any DNAi oligonucleotide that is owned, controlled, developed or licensed by Licensee (or its Affiliate) for use in the Field of Use, such as NT200 through PNTl 000.
DNAi means all single stranded oligonucleotides that affect the non-transcribed region of a gene target. DNAi does not include RNAi, antisense and microRNA oligonucleotides that base pair with mRNAs, microRNAs or pre-mRNAs to affect expression of a gene, directly or indirectly.
PNT2258 is Licensee first DNAi oligonucleotide targeted against the anti-apoptotic bcl-2 oncogene and encapsulated in Marina's SMARTICLESÂ® technology. This novel delivery technology offers protection for the DNAi oligonucleotide during systemic administration with good circulation times and extrahepatic tumor exposure. DNAi are short single-strand unmodified oligonucleotides designed to silence genes by interfering with DNA. The DNAi silencing approach is differentiated from that of RNAi, antisense or miRNA in that it targets genomic sequences within the noncoding region of DNA disrupting transcription. The progress and delivery validation in the clinic this past year on the novel DNAi-SMARTICLESÂ® formulation gives us confidence to bring forward more first-in-class drug candidates alone or with partners.
IPSCIO Record ID: 291110
Ciprofloxacin means the chemical compound known as ciprofloxacin, whose more specified chemical name is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid and all pharmaceutically active salts thereof.
AERx Device means the durable hand-held device developed by Licensee for the delivery of Ciprofloxacin by inhalation and known as the AERx Device, as such device may be modified pursuant to the Agreement.
Loading Patents means the patents owned by University and exclusively licensed to Licensor and set out in Agreement.
5,800,833 – Method for loading lipid vesicles
5,785,987 – Method for loading lipid vesicles
Sphingosome Patents means the Patents owned by Licensor and set out in this Agreement.
5,543,152 – Sphingosomes for enhanced drug delivery
Licensed Patents means the Loading Patents and the Sphingosome Patents.
Patent means (a) all patent applications filed or having legal force in any country owned or controlled by Licensor as of the Effective Date; (b) all patents that have issued or in the future issue therefrom owned or controlled by Licensor as of the Effective Date, including without limitation utility, model and design patents and certificates of invention; and (c) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions (including supplemental protection certificates), additions, registrations or confirmations to or of any such patent applications and patents.
Licensor Liposome Technology means Licensorâ€™s proprietary liposomal drug delivery system that encapsulates drugs in sphingomyelin/cholesterol liposomes using a proton gradient generated by either an ionophore or methylammonium sulfate.
Ciprofloxacin is a fluoroquinolone (flor-o-KWIN-o-lone) antibiotic that fights bacteria in the body. It is used to treat different types of bacterial infections, including skin infections, bone and joint infections, respiratory or sinus infections, urinary tract infections, and certain types of diarrhea.
IPSCIO Record ID: 314332
Licensee desires to obtain, and Licensor is willing to grant, an exclusive, worldwide license to the proprietary DepoFoamÂ® delivery system in order to develop and commercialize formulations of Liraglutide.
Formulation Intellectual Property means all Know-How arising from activities performed under this Agreement regarding formulations of Liraglutide with DepoFoam and/or methods or processes for making or using such formulations.
Liraglutide means Licensees proprietary, human Glucagon-Like Peptide-1 (GLP-1} analogue.
Liraglutide is a medication used to treat diabetes mellitus type 2 and obesity.